Closed-Loop and Artificial Intelligence–Based Decision Support Systems

Bergenstal RM , Garg S , Weinzimer SA , et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA, 2016; 316:1407–1408.

Brown SA , Kovatchev BP , Raghinaru D , et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med, 2019; 381: 1707–1717.

Breton MD , Kanapka LG , Beck RW , et al. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med, 2020; 383: 836–845.

Bergenstal RM , Nimri R , Beck RW , et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet, 2021; 397(10270): 208–219.

Ware J , Boughton CK , Allen JM , et al. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. Lancet Digit Health, 2022; 4: e245-e255.

Benhamou PY , Franc S , Reznik Y , et al. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial. Lancet Digit Health, 2019; 1: e17–e25.

Brown SA , Forlenza GP , Bode BW , et al. Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care, 2021; 44: 1630–1640.

Da Silva J , Bosi E , Jendle J , et al. Real-world performance of the MiniMed™ 670G system in Europe. Diabetes Obes Metab, 2021; 23: 1942–1949.

Breton MD , Kovatchev BP . One year real-world use of Control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther, 2021; 23: 601-608

Silva JD , Lepore G , Battelino T , et al. Real-world performance of the MiniMed 780G system: first report of outcomes from 4120 users. Diabetes Technol Ther, 2022; 24: 113–119.

Kovatchev BP. Differences in Closed Loop Algorithms—Benefits and Limitations. New Orleans, LA: American Diabetes Association's 82nd Scientific Sessions; 2022.

Kovatchev, Singh H , Mueller L , Linda Gonder-Frederick LA . Bio-behavioral changes following transition to automated insulin delivery: a large real-life database analysis. Diabetes Care, 2022; 45(11): 2636–2643.

Tauschmann M , Thabit H , Bally L , et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet, 2018; 392(10155):1321–1329.

McAuley SA , Trawley S , Vogrin S , et al. Closed-loop insulin delivery versus sensor-augmented pump therapy in older adults with type 1 diabetes (ORACL): a randomized, crossover trial. Diabetes Care, 2022; 45: 381–390.

Boughton CK , Tripyla A , Hartnell S , et al. Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. Nat Med, 2021; 27: 1471–1476.

Tornese G , Carletti C , Giangreco M , Nisticò D , Faleschini E , Barbi E . Carbohydrate tolerance threshold for unannounced snacks in children and adolescents with type 1 diabetes using an advanced hybrid closed-loop system. Diabetes Care, 2022; 45: 1486–1488.

Morrison D , Zaharieva DP , Lee MH , et al. Comparable glucose control with fast-acting insulin aspart versus insulin aspart using a second-generation hybrid closed-loop system during exercise. Diabetes Technol Ther, 2022; 24: 93–101.

Bode B , Carlson A , Liu R , et al. Ultrarapid lispro demonstrates similar time in target range to lispro with a hybrid closed-loop system. Diabetes Technol Ther, 2021; 23: 828–836.

Lee MH , Paldus B , Vogrin S , et al. Fast-acting insulin aspart versus insulin aspart using a second-generation hybrid closed-loop system in adults with type 1 diabetes: a randomized, open-label, crossover trial. Diabetes Care, 2021; 44: 2371–2378.

Garcia-Tirado J , Diaz JL , Esquivel-Zuniga R , et al. Advanced closed-loop control system improves postprandial glycemic control compared with a hybrid closed-loop system following unannounced meal. Diabetes Care, 2021; 44: 2379–2387.

Forlenza GP , Breton MD , Kovatchev BP . Candidate selection for hybrid closed loop systems. Diabetes Technol Ther, 2021; 23: 760–762.

Forlenza GP , Carlson AL , Galindo RJ , et al. Real-world evidence supporting tandem Control-IQ hybrid closed-loop success in the Medicare and Medicaid type 1 and type 2 diabetes populations. Diabetes Technol Ther 2022 Jul 26. doi: 10.1089/dia.2022.0206. Online ahead of print.

2022 Survey of Physician Appointment Wait Times [tool online], August 29, 2022. Available at www.merritthawkins.com/trends-and-insights/article/surveys/2022-physician-wait-times-survey.

Fang M , Wang D , Coresh J , Selvin E . Trends in diabetes treatment and control in U.S. adults, 1999-2018. N Engl J Med, 2021; 384: 2219–2228.

American Diabetes Associaton. Overcoming therapeutic inertia [set of online resources], accessed November 2022 . Available at www.therapeuticinertia.diabetes.org/practice-improvement-resources.

Fleming GA , Petrie JR , Bergenstal RM , Holl RW , Peters AL , Heinemann L . Diabetes digital app technology: benefits, challenges, and recommendations. a consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care, 2020; 43: 250–260.

Bisio A , Anderson S , Norlander L , et al. Impact of a novel diabetes support system on a cohort of individuals with type 1 diabetes treated with multiple daily injections: a multicenter randomized study. Diabetes Care, 2022; 45: 186–193.

Ferstad JO , Vallon JJ , Jun D , et al. Population-level management of type 1 diabetes via continuous glucose monitoring and algorithm-enabled patient prioritization: precision health meets population health. Pediatr Diabetes, 2021; 22: 982–991.

Oser TK , Cucuzzella M , Stasinopoulos M , Moncrief M , McCall A , Cox DJ . An innovative, paradigm-shifting lifestyle intervention to reduce glucose excursions with the use of continuous glucose monitoring to educate, motivate, and activate adults with newly diagnosed type 2 diabetes: pilot feasibility study. JMIR Diabetes, 2022; 7: e34465.

Ware J , Allen JM , Boughton CK , et al. Randomized trial of closed-loop control in very young children with type 1 diabetes. N Engl J Med, 2022; 386: 209–219.

Abraham MB , de Bock M , Smith GJ , et al. Effect of a hybrid closed-loop system on glycemic and psychosocial outcomes in children and adolescents with type 1 diabetes: a randomized clinical trial. JAMA Pediatr, 2021; 175: 1227–1235.

Messer LH , Berget C , Pyle L , et al. Real-world use of a new hybrid closed loop improves glycemic control in youth with type 1 diabetes. Diabetes Technol Ther, 2021; 23: 837–843.

Garcia-Tirado J , Farhy L , Nass R , et al. Automated insulin delivery with SGLT2i combination therapy in type 1 diabetes. Diabetes Technol Ther, 2022; 24: 461–470.

Haidar A , Lovblom LE , Cardinez N , et al. Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial. Nat Med, 2022; 28: 1269–1276.

Schoelwer MJ , Kanapka LG , Wadwa RP , et al. Predictors of time-in-range (70-180 mg/dL) achieved using a closed-loop control system. Diabetes Technol Ther, 2021; 23: 475–481.

Vetrani C , Calabrese I , Cavagnuolo L , et al. Dietary determinants of postprandial blood glucose control in adults with type 1 diabetes on a hybrid closed-loop system. Diabetologia, 2022; 65: 79–87.

Paldus B , Morrison D , Zaharieva DP , et al. A Randomized crossover trial comparing glucose control during moderate-intensity, high-intensity, and resistance exercise with hybrid closed-loop insulin delivery while profiling potential additional signals in adults with type 1 diabetes. Diabetes Care, 2022; 45: 194–203.

Proietti A , Raggio M , Paz M , et al. Six-month glycemic control with a hybrid closed-loop system in type 1 diabetes patients in a Latin American country. Diabetes Technol Ther, 2022; 24: 220–226.

Petrovski G , Al Khalaf F , Campbell J , et al. Glycemic outcomes of advanced hybrid closed loop system in children and adolescents with type 1 diabetes, previously treated with multiple daily injections (MiniMed 780G system in T1D individuals, previously treated with MDI). BMC Endocr Disord, 2022; 22: 80.

Murata Y , Takita M , Kami M . Closed-loop control in very young children with type 1 diabetes. N Engl J Med, 2022; 386: 1482.

Ring BL . Closed-loop control in very young children with type 1 diabetes. N Engl J Med, 2022; 386: 1482.

Forlenza GP , Ekhlaspour L , DiMeglio LA , et al. Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial. Pediatr Diabetes, 2022; 23: 324–329.

Ekhlaspour L , Schoelwer MJ , Forlenza GP , et al. Safety and performance of the tandem t:slim x2 with Control-IQ automated insulin delivery system in toddlers and preschoolers. Diabetes Technol Ther, 2021; 23: 384–391.

Buckingham BA , Forlenza GP , Sherr J , et al. Safety and performance of the Omnipod hybrid closed-loop system in young children aged 2-6 years with type 1 diabetes. Diabetes, 2019; 68(Supplement_1): 215-OR .

Salehi P , Roberts AJ , Kim GJ . Efficacy and safety of real-life usage of MiniMed 670G Automode in children with type 1 diabetes less than 7 years old. Diabetes Technol Ther, 2019; 21: 448–451.

Cobry EC , Kanapka LG , Cengiz E , et al. Health-related quality of life and treatment satisfaction in parents and children with type 1 diabetes using closed-loop control. Diabetes Technol Ther, 2021; 23: 401–409.

Rosenstock J , Marquard J , Laffel LM , et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care, 2018; 41: 2560–2569.

Ekhlaspour L , Town M , Raghinaru D , Lum JW , Brown SA , Buckingham BA . Glycemic outcomes in baseline hemoglobin A1c subgroups in the International Diabetes Closed-Loop Trial. Diabetes Technol Ther, 2022; 24: 588–591.

Castañeda J , Mathieu C , Aanstoot HJ , et al. Predictors of time in target glucose range in real-world users of the MiniMed 780G system. Diabetes Obes Metab 2022 Jul 6. doi: 10.1111/dom.14807. Online ahead of print.

Phillip M , Nimri R , Bergenstal RM , et al. Consensus recommendations for the use of automated insulin delivery (AID) technologies in clinical practice. Endocr Rev 2022 Sep 6;bnac022. doi: 10.1210/endrev/bnac022. Online ahead of print.

Liu J , Miller K , Kelly C , et al. Automated insulin delivery use among 12,065 T1D exchange registry participants. Diabetes, 2022; 71(Supplement_1): 289-OR.

Vega-López S , Ausman LM , Griffith JL , Lichtenstein AH . Interindividual variability and intra-individual reproducibility of glycemic index values for commercial white bread. Diabetes Care, 2007; 30: 1412–1417.

Hinshaw L , Dalla Man C , Nandy DK , et al. Diurnal pattern of insulin action in type 1 diabetes: implications for a closed-loop system. Diabetes, 2013; 62: 2223–2229.

Zaharieva DP , Messer LH , Paldus B , O'Neal DN , Maahs DM , Riddell MC . Glucose control during physical activity and exercise using closed loop technology in adults and adolescents with type 1 diabetes. Can J Diabetes, 2020; 44: 740–749.

Vigersky RA , Velado K , Zhong A , Agrawal P , Cordero TL . The effectiveness of virtual training on the MiniMed™ 670G System in people with type 1 diabetes during the COVID-19 pandemic. Diabetes Technol Ther, 2021; 23: 104–109.

Pinsker JE , Singh H , McElwee Malloy M , et al. A virtual training program for the Tandem t:slim x2 insulin pump: implementation and outcomes. Diabetes Technol Ther 2021;23: 467–470.

McAuley SA , Lee MH , Paldus B , et al. Six months of hybrid closed-loop versus manual insulin delivery with fingerprick blood glucose monitoring in adults with type 1 diabetes: a randomized, controlled trial. Diabetes Care, 2020; 43: 3024–3033.

de Bock M , McAuley SA , Abraham MB , et al. Effect of 6 months hybrid closed-loop insulin delivery in young people with type 1 diabetes: a randomised controlled trial protocol. BMJ Open, 2018; 8: e020275.

Petrovski G , Al Khalaf F , Campbell J , Fisher H , Umer F , Hussain K . 10-Day structured initiation protocol from multiple daily injection to hybrid closed-loop system in children and adolescents with type 1 diabetes. Acta Diabetol, 2020; 57: 681–687.

Paramesh S , Shah L , Mohammed J , et al. Artificial intelligence offers significant rate of remision for type 2 diabetes compared to standart care. Diabetes, 2022; 71(Supplement_1): 4-LB.